Drug intelligence / Profile preview

atropine + dexamethasone

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Ophthalmic

Overview

**Atropine + dexamethasone** is a fixed-dose ophthalmic combination used for inflammatory anterior-eye conditions, including uveitis. Atropine is a nonselective muscarinic receptor antagonist that produces mydriasis and cycloplegia, helping relieve ciliary spasm and prevent posterior synechiae. Dexamethasone is a synthetic glucocorticoid that suppresses ocular inflammatory signaling through glucocorticoid receptor activation. A marketed formulation, Dexapin, contains atropine 1% and dexamethasone 0.10% as eye drops. ([1mg.com](https://www.1mg.com/drugs/dexapin-1-0.10-eye-drop-254879))

Brand names: Dexapin
Other names: atropine/dexamethasonedexamethasone + atropine

Targets

GR (Glucocorticoid receptor)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on atropine + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atropine + dexamethasone.

Explore the full profile